Refine by
Potential Therapeutic Suppliers & Manufacturers
50 companies found
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inVienna, AUSTRIA
Aposcience AG is a worldwide innovation leader in the field of regenerative medicine. Regenerative medicine has the potential to transform the treatment for diseases with high medical need, as the tissues afflicted by the disease process can be ...
based inAu, Zurich, SWITZERLAND
Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ ...
based inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, ...
based inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. Dual targeting of 4-1BB and OX40 provides synergistic ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
EX VIVO Human Platforms for Cardiovascular Drug Discovery. Broadly defined, cardiovascular disease is the leading cause of death for men and women across most racial and ethnic groups in the United States with one person dying approximately every 34 ...
based inSeattle, WASHINGTON (USA)
Impel Pharmaceuticals Inc. is a commercial stage pharmaceutical company focused on developing and providing transformative therapies that unlock the full potential of therapeutic molecules for people suffering from diseases with high unmet medical ...
Impel Pharmaceuticals has developed a proprietary drug delivery technology system that targets the vascular-rich upper nasal space,1 with multiple clinical trials suggesting rapid absorption and consistent drug bioavailability with ease of use in ...
based inHackensack, NEW JERSEY (USA)
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development ...
based inNew York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
based inBrisbane City, AUSTRALIA
Microba’s precise microbiome analysis is built on the expertise of our innovative team at the leading edge of microbiome science. Our approach to microbiome analysis is enabling new discoveries and advancing the understanding of the microbiome in ...
Developing novel therapeutics from the human microbiome; The uncultured portion of the human gut microbiome, which is the majority of microbial species, represents untapped therapeutic opportunity. Microba has established a platform for drug ...
based inDallas, TEXAS (USA)
Berkshire Biomedical is developing a Revolutionary Secure Medication Delivery for the Intended User combined with a Physician-Enabled Management System. Secure Medication Delivery with Remote Monitoring and Compliance Support is the Most Efficient ...
based inDijon, FRANCE
At Exeliom Biosciences, we develop novel therapeutic approaches to unleash the therapeutic potential of key players in the Microbiome - Host interactions to fight immune-mediated diseases, starting with inflammatory bowel diseases. There is a time ...
Faecalibacterium prausnitzii (F. prau), a key bacterium to treat Crohn’s Disease Meet Faecalibacterium prausnitzii (F. prau) WHAT IS F. prau? F. prau, is a dominant member of the healthy gut microbiome. It accounts for 5% to 15% of the total ...
based inChicago, ILLINOIS (USA)
Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause ...
based inAustin, TEXAS (USA)
Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing ...
based inNoida, INDIA
Advancells is a research-oriented company, focussed on offering authentic, high-quality primary cells including stem cells for research studies, stem cell therapy, preclinical analysis, and even as in vitro tools for clinical research. We wish to be ...
based in, NEW YORK (USA)
'Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug ...
Creative Biomart provides drug analysis service for pre-clinical drugs and natural products on their physical and chemical properties. Our services include three main assays: pre-clinical pharmaceutical property analysis, pharmacokinetics analysis ...
based inPalo Alto, CALIFORNIA (USA)
BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity. To ...
Encaleret is an investigational small molecule antagonist of the calcium sensing receptor (CaSR) being studied in disorders of calcium homeostasis, including autosomal dominant hypocalcemia type 1 (ADH1). Individuals with ADH1 have gain-of-function ...